scholarly journals Comparative effectiveness of anti-fibrosis treatment in patients after HCV infection and in patients with non-alcoholic fatty liver disease (NAFLD)

2021 ◽  
Vol 11 (2) ◽  
pp. 222-229
Author(s):  
Nadiia Gavryliuk ◽  
Ihor Hospodarskyy ◽  
Oksana Prokopchuk ◽  
Olha Krekhovska-Lepiavko ◽  
Borys Lokay ◽  
...  

Due to the high prevalence of NAFLD and CHC, these two pathologies will progress and contribute to the progression of fibrosis. Unfortunately, nowadays there is no single treatment strategy for such patients. That is why, in most cases a variety of treatment regimens on the base of different hepatoprotectors are prescribed. Instead, there is evidence that the use of some hepatoprotectors has no influence on fibrotic processes in the liver or can even exacerbate them. In order to study the antifibrotic effect of hepatoprotectors in patients with posthepatic fibrosis after HCV infection and in patients with NAFLD, we studied the results of prescribing the hepatoprotective drug bicyclol.

2021 ◽  
Vol 17 (4) ◽  
pp. 62-67
Author(s):  
M.A. Livzan ◽  
◽  
T.S. Krolevets ◽  
T.V. Kostoglod ◽  
A.V. Kostoglod

The high prevalence of non-alcoholic fatty liver disease and its association with diseases of the metabolic profile causes the interest of doctors of various specialties in the management of patients with this pathology. Due to the accumulation of data on risk factors and disease progression, approaches and attitudes about previously harmless pathology have evolved to understand its potential danger. The formation of the correct approach to the management of patients with non-alcoholic fatty liver disease is a priority task. In this publication, we have analyzed and systematized data from literature concerning the most common problems (mistakes) in the curation of patients with non-alcoholic fatty liver disease.


JGH Open ◽  
2019 ◽  
Vol 3 (2) ◽  
pp. 133-139 ◽  
Author(s):  
Ajay Duseja ◽  
Shaneez Najmy ◽  
Suchet Sachdev ◽  
Arnab Pal ◽  
Rati Ram Sharma ◽  
...  

2020 ◽  
Vol 92 (2) ◽  
pp. 48-54 ◽  
Author(s):  
N. A. Cherkashchenko ◽  
M. A. Livzan ◽  
T. S. Krolevets

Aim.To update information about comorbidity of non-alcoholic fatty liver disease (NAFLD) and gallstones disease (GD), evaluation of clinical and laboratory data, including insulin, leptin and adiponectin in individuals with NAFLD in combination with GD. Materials and methods.According to the design, we conducted an open comparative study of 169 patients with NAFLD. The following comparison groups were formed: group 1 (n=95) patients with NAFLD without GD, group 2 (n=35) patients with NAFLD and GD and group 3 (n=39) patients with NAFLD, GD and previous cholecystectomy. Results.A high prevalence of coronary heart disease was found in the group of patients with GD and cholecystectomy (2=6.198,p0.05); positive, statistically significant correlation relationships of cholelithiasis, cholecystectomy with ischemic heart disease (rs=0.172,p0.05 andrs=0.241,p0.05, respectively). There was a statistically significant decrease in total bilirubin and total protein in patients of group 3 (H=7.376,p0.03 and H=6.345,p0.04). The level of leptin is statistically significantly higher and positively interrelated with cholecystectomy (H=5.812,p0.05,rs=0.313,p0.05). Conclusion.Patients with NAFLD, GD and previous cholecystectomy have a high prevalence of coronary heart disease; the phenomenon of insulin and leptin resistance, high level of adiponectin were revealed in patients with NAFLD and gallstones; hyperleptinemia was observed among patients with NAFLD, GD after cholecystectomy.


2012 ◽  
Vol 4 (2) ◽  
Author(s):  
Mohammad Ebrahim Ghamar-Chehreh ◽  
Mohsen Amini ◽  
Hossein Khedmat ◽  
Fatemeh Daraei ◽  
Reza Mohtashami ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document